biotech radar UNIVERSE
Companies Covered in our Universe
Deal Monitor – European Public Biotech Companies
Financing Monitor – European Public Biotech Companies
Latest News
Snapshot of Centerview Partners in Biopharma M&A over 2023 and 2024
In this short post, I propose a quick snapshot of the M&A transactions Centerview have been involved in, during 2023 and 2024, to show by the data that the biopharma acquisitions are their forte. As the WSJ reported yesterday, the shareholders of Centerview Partners are exploring the sale of a stake in the boutique bank.[…]
European listed biotech landscape: 2021 review and outlook for 2022
Table of Content 1. 2021, a year to forget for the sector, or to learn from? 2. Status on COVID-19 3. Key Events in 2021 (Morphosys transformative deal, main approvals, Galapagos, Oncopeptides) 4. 2021 Highlights (Approval rates, IPOs & new listings, financing) 5. 2021 Lowlights (Clinical trial success rates, performances of commercial launches, Sweden, deals)[…]
European listed biotech landscape: 2020 review and outlook for 2021
Table of Content 1. Intro on COVID-19 2. How the European listed biotech companies try to help for vaccines and therapies against COVID-19 3. 2020 Highlights (financing, Genmab, Morphosys, approvals, “Billion Euro Biotech Club”, valuations) 4. 2020 Lowlights (Galapagos, Genfit, DBV, IPOs, AIM) 5. 2020 Deals and M&As 6. 2020 Stock and Index Performances 7.[…]
Summary of the COVID-19 vaccine supply agreements for Europe (incl. the UK & Switzerland), the US, Japan, Canada, Australia (28/02/2021 update)
Change log: * The updates from 08/11/2020 and later include additional data in the tables since the first publication on 25/08/2020, and only in the tables. * Calculation errors were corrected on 20/11/2020 and on 12/12/2020 (errors in aggregate nb of doses and avg nb of course/inh. for the US data). * Major update for[…]
The European listed biotech companies with COVID-19 programs: status & follow-up (updated 13/01/2021)
In the context of the COVID-19/SARS-Cov-2 pandemic, many biopharma companies throughout the world try to bring therapeutic options, on top of the topic of testing, which will not be focused on here. Some European listed companies have joined this international effort over the past weeks, and especially since the month of March. Vaccine development has[…]
European listed biotech companies: stock performance tracking after the coronavirus outbreak (updated)
The markets have been very volatile lately, and the main indices have known historical sessions in terns or performances on last Monday (09/03/2020), and even worse on last Thursday (12/03/2020, a real “Black Thursday” of the 21st century). That day, the European markets saw either their largest falls ever, either their worst performances since 19/10/1987[…]
European listed biotech landscape: 2019 review and outlook for 2020
2018 was a very bad year for the European biotech landscape, so the question was whether a rebound could take place or not in 2019, in a global environment where the recurring macro themes basically remained unchanged: US/China trade war, Brexit, rates, recession fears (you know, the one that is announced every year for the[…]
ASH 2019 abstract list & presentations
So far, we listed 39 abstracts from the European listed biotech companies or their partners for the ASH 2019 Annual meeting, excluding those relating to daratumumab (16 abstracts by Janssen/JNJ). Morphosys will present 7 abstracts and Oncopeptides 6. Cellectis and partners gather 4 presentations. Argenx will have 2 oral presentations, one for efgartigimod in ITP,[…]
Stock performances of European biotech companies: status at the end of Q3 2019
Stock performances of the European listed biotech companies were positive at the end of 30/09/2019, on average. However, the median performance is -9.0%, leads to an easy conclusion: the average performance was driven by outliers on the gaining side. Unlike 2018, where overall, there was a common pattern downwards, 2019 data are heavily spread among[…]
Deal Monitor: status at the end of Q3 2019
It’s time to make a top view status of the deal activity for the 150+ European listed biotech companies in our universe. The data below include deals from all categories (R&D collaborations, Out-Licensing deals, Supply/Distribution deals, JV, IP licensing, Sales/Divestments), except the in-licensing deals. Please refer to our introductory report for more details and explanations.[…]
Record-breaking financing for European public biotech companies in Q3 2019 but…
The third quarter of 2019 has been historical for European listed biotechs. The total amounts raised or secured by the 150+ listed companies under coverage reached 2168 mEUR, all categories included (equity issue, US IPO, warrants/equity lines, debt/non-dilutive sources). That makes this quarter likely the best ever… However, this number hides a much less positive[…]
ESMO 2019 abstract list & presentations
31 abstracts, at least, should be presented at the coming ESMO 2019 meeting on therapies or products from European biotech companies in our universe. The meeting kicks off at the end of the week. Faron managed to get a Late-Breaking Abstract spot (Faron says it was accepted as a Poster Discussion), which is quite rare[…]
The European landscape of listed biotech companies: 2018 review (Part 5)
This is the fifth part of our 2018 review dedicated to the European public biotech landscape. Check out Part 1, Part 2, Part 3 or Part 4. The full report is now available here. Part 5 – Table of Content 7. Deals 8. Portrait of a “typical” biotech company listed in Europe 9. Conclusion 2018[…]
The European landscape of listed biotech companies: 2018 review (Part 4)
This is the fourth part of our 2018 review dedicated to the European public biotech landscape. Check out Part 1, Part 2 or Part 3. The full report is now available here. Part 4 – Table of Content 5. Financing 6. Other financial metrics: cash burn, extra cash sources, cash balance, profits & losses 6.1[…]
The European landscape of listed biotech companies: 2018 review (Part 3)
This is the third part of our 2018 review dedicated to the European public biotech landscape. Check out Part 1, or Part 2. The full report is now available here. Part 3 – Table of Content 3. Market data 3.1 Market capitalization 3.2 Stock performances 3.3 Market Liquidity 4. Employment References 3. Market data 3.1[…]
The European landscape of listed biotech companies: 2018 review (Part 2)
This is the second part of our 2018 review dedicated to the European public biotech landscape. Check out the introduction and first part here. The full report is now available here. Part 2 – Table of Content 2. R&D Pipeline & Commercial Products 2.1 Unique product candidates in active clinical development, indications and therapeutic areas[…]
The European landscape of listed biotech companies: 2018 review (Part 1)
This review is an introduction to the universe covered by Biotellytics, publisher of biotechradar.eu, a business intelligence service on the landscape of the European biotech companies listed on the main European stock exchanges. This service aims at providing insights and data at company level for investors, as well as consolidated data at the European level[…]
DATA & INTEL FOR A 360° View on the Public Biotech Landscape in Europe
How We Help Investors & Professionals in Life Sciences
DISCOVER NEW COMPANIES WITH OUR BROAD COVERAGE
Our data coverage is focused on the European biotech companies listed on the main stock exchange platforms in 13 countries: Germany, France, Belgium, Netherlands, Switzerland, UK, Ireland, Spain, Italy and the Nordic countries (Denmark, Sweden, Norway, Finland). The coverage only includes biotech companies developping therapeutics, we DO NOT COVER: pharma companies, the medtech landscape, nor the associated service companies (CRO, CMO, Drug Discovery, etc…), with few exceptions nevertheless. We include some potentially high-growth companies in the field of diagnostics, as well as some specialty companies.
ACCESS INSIGHTS, GAIN TIME, SPOT OPPORTUNITIES
We provide timely detailed data on the pipeline of all the companies, representing more than 1200 programs currently at the clinical stage (more than 2000 programs overall). Our service is both a discovery tool for potential new opportunities, and a platform tracking any event from the covered companies. It may also be seen as a promoting support for this universe, even though we are completely independent. Maximize knowledge in a short period, and gain a tremendous amount of time in your due dilligence and research process. We do not cover the scientific analysis part (results from clinical trials).
FINANCIAL DATA, MARKET DATA, DEALS, FINANCINGS…
We provide up-to-date relevant financial data on the companies: cash positions, cash burn rates, live cash estimates, cash runways, income statements. Don’t get lost in the numerous financing schemes with our detailed tracking of the financing lines (as much as decently possible). Access our database of financing agreements, parse our records of the various partnerships between the companies and third parties. Keep track of the stocks on our free dashboards (disclaimers apply), and more.
INDICATORS AND ANALYTICS
We will strive to deliver specific insights on the public European biotech landscape by leveraging our large -and still growing- set of data. We aim to provide intelligence, highlighting dynamics, as well as identifying trends in various relevant areas. We will also provide a picture of the landscape periodically. Some analysis may be published in the form of reports, reserved to our clients or made public.
Basic Plan subscription main features (retail customers)
Company Dashboard on biotechradar.eu
Event Screener on biotechradar.eu
Data from 14 Countries, 10 Languages, 8 European Equity Markets, 7 CurrenciesCheck out our introductory review
Biotech Radar Service
All in one place, for PROs only
European hub for investors and professionnals
in Life Sciences
Our Service covers the pipeline, the commercial products (therapeutics only), the financials, the deals, the financing operations of the European public biotech companies, and more.
The market data can be accessed for free.
We DO NOT provide any recommendations on any financial instruments. We own our data and we collect them from corporate or well-trusted sources (e.g. clinicaltrials.gov). We operate as an independent company.
Pipeline
All the programs, all the product candidates & all the commercial products
Financials
All the main financial figures
Market Data
in our coverage universe
Deals & Financing
Deal DB, Financing DB